文献速递白血病

BIM 缺失多态性增强白血病干/祖细胞存活并损害靶向治疗反应

The BIM deletion polymorphism potentiates the survival of leukemia stem and progenitor cells and impairs response to targeted therapies.
PubMed 文献 · Leukemia · 2024-10-22

研究构建携带东亚常见 BIM 缺失多态性(BDP)的人源化小鼠模型并引入慢性髓性白血病(CML)模型,发现 BDP 使 CML 细胞竞争适应度提高三倍、疾病更具侵袭性,并使 CML 干/祖细胞(LSPCs)对伊马替尼诱导的细胞死亡几乎完全抵抗;BH3 谱分析显示 BDP LSPCs 对 MCL-1 拮抗剂存在治疗脆弱性,并在原代人 LSPCs 和体内得到验证。

要点

  • BDP 使 CML 细胞竞争适应度提高三倍,导致疾病更具侵袭性。
  • BDP 使 CML 干/祖细胞对伊马替尼诱导的细胞死亡几乎完全抵抗。
  • BDP LSPCs 对 MCL-1 拮抗剂存在治疗脆弱性,在原代人 LSPCs 和体内得到验证。

核心结论

  • BDP 增强白血病干/祖细胞的存活并损害靶向治疗反应,提示人源多态性可作为定制治疗的伴随诊断。

研究设计与样本

  • 研究构建携带 BIM 缺失多态性(BDP)的人源化小鼠模型,并将 BDP 小鼠与慢性髓性白血病(CML)模型杂交以研究白血病起始。
  • 利用 BH3 谱分析鉴定 BDP LSPCs 的治疗脆弱性,并在原代人 LSPCs 和体内进行验证。

主要发现

  • BDP 使 CML 细胞竞争适应度提高三倍,导致疾病更具侵袭性。
  • BDP 使 CML 干/祖细胞对伊马替尼诱导的细胞死亡几乎完全抵抗。
  • BH3 谱分析显示 BDP LSPCs 对 MCL-1 拮抗剂存在治疗脆弱性,并在原代人 LSPCs 和体内得到验证。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

One sixth of human cancers harbor pathogenic germline variants, but few studies have established their functional contribution to cancer outcomes. Here, we developed a humanized mouse model harboring a common East Asian polymorphism, the BIM deletion polymorphism (BDP), which confers resistance to oncogenic kinase inhibitors through generation of non-apoptotic splice isoforms. However, despite its clear role in mediating bulk resistance in patients, the BDP's role in cancer stem and progenitor cells, which initiate disease and possess altered BCL-2 rheostats compared to differentiated tumor cells, remains unknown. To study the role of the BDP in leukemia initiation, we crossed the BDP mouse into a chronic myeloid leukemia (CML) model. We found that the BDP greatly enhanced the fitness of CML cells with a three-fold greater competitive advantage, leading to more aggressive disease. The BDP conferred almost complete resistance to cell death induced by imatinib in CML stem and progenitor cells (LSPCs). Using BH3 profiling, we identified a novel therapeutic vulnerability of BDP LSPCs to MCL-1 antagonists, which we confirmed in primary human LSPCs, and in vivo. Our findings demonstrate the impact of human polymorphisms on the survival of LSPCs and highlight their potential as companion diagnostics for tailored therapies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Yu M, Nah GSS, Krishnan V, et al. The BIM deletion polymorphism potentiates the survival of leukemia stem and progenitor cells and impairs response to targeted therapies. Leukemia. 2024. PMID: 39438588. doi:10.1038/s41375-024-02418-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。